1337. SYN-004 (ribaxamase) Protects the Gut Microbiome of Patients Treated with Ceftriaxone from Disruption and Reduces the Emergence of Antimicrobial Resistance
Session: Poster Abstract Session: Novel Agents
Friday, October 5, 2018
Room: S Poster Hall
Background: When β-lactam antibiotics are administered intravenously, a significant portion of each dose can be excreted through the bile into the intestine. This excess antibiotic disrupts the balance of the gut microbiome making the recipient more susceptible to certain infections and can lead to the emergence of antimicrobial resistance. SYN-004 (ribaxamase) is an orally administered β-lactamase designed to be given with IV β-lactam antibiotics (penicillins and cephalosporins) to degrade excess antibiotics excreted into the upper GI tract before they can disrupt the gut microbiome and resistome.

Methods: During a Phase 2b, clinical study with ribaxamase which demonstrated a significant reduction in Clostridium difficile infection in patients receiving ceftriaxone + ribaxamase, longitudinal fecal samples were collected from the patients. DNA extracted from these samples was 16S rRNA and whole genome sequenced, and the sequences were analyzed for changes in the gut microbiome and resistome. Statistical analyses were performed to determine correlations between changes in the gut microbiome and resistome and clinical study data.

Results: Sequence analyses revealed that ribaxamase protected the integrity of the gut microbiome, including preventing enterococcal mono-domination (defined as >30% of the microbiome being from one genus), and identified over 1300 AMR genes in the gut resistome. LefSe analysis of the gut resistome identified a family of β-lactamases (CfxA) and vancomycin resistance genes which demonstrated a significant increase in placebo-treated vs. ribaxamase-treated patients from pre-to post-antibiotics. Analysis by qPCR supported both new acquisition of these genes and expansion of existing AMR pools. Further statistical analyses demonstrated significant correlations between changes in the gut resistome and clinical study parameters including β-lactamase gene frequency and study drug assignment, and efflux pump gene frequency and vancomycin resistance.

Conclusion: Taken together, these findings demonstrated that coadministration of ribaxamase with IV β-lactam antibiotics can protect the integrity of the gut microbiome and may help limit the emergence of AMR induced by these antibiotics.

John Kokai-Kun, PhD1, Charles Le, PhD1, Kenneth Trout, MS1, Julia Cope, PhD2 and Joseph Sliman, MD, PhD1, (1)Synthetic Biologics, Inc., Rockville, MD, (2)Diversigen, Inc., Houston, TX

Disclosures:

J. Kokai-Kun, Synthetic Biologics, Inc.: Employee , Salary .

C. Le, Synthetic Biologics, Inc.: Employee , Salary .

K. Trout, Synthetic Biologics, Inc.: Employee , Salary .

J. Cope, None

J. Sliman, Synthetic Biologics, Inc.: Employee , Salary .

See more of: Novel Agents
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.